Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects of Chinese descent with full Chinese parentage.~* Diagnosis of Crohn's disease (CD) for at least 3 months prior to Week 0.~* Crohn's Disease Activity Index (CDAI) greater than or equal to 220 and less than or equal to 450 despite treatment with oral corticosteroids and/or immunosuppressants.~* Subject has a negative Tuberculosis (TB) Screening Assessment.~* Subject has elevated high sensitivity C-reactive protein (hs-CRP) during the Screening Period.~Exclusion Criteria:~* Subject with ulcerative colitis or indeterminate colitis.~* Subject who has had a surgical bowel resection within the past 6 months or who is planning any resection at any time point in the future.~* Subject with an ostomy or ileoanal pouch.~* Subject who has short bowel syndrome.~* Subject with symptomatic known obstructive strictures.~* Subject with an internal or external fistula (with the exception of an anal fistula without abscess).~* Active, or chronic or recurring infections, or active tuberculosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Induction Regimen (Type: EXPERIMENTAL): Double-blind period (Weeks 0-8): Placebo at Weeks 0 and 2, followed by adalimumab 160 mg at Week 4, 80 mg at Week 6.~Open label period: adalimumab 40 mg every other week (eow) from Week 8 through last dose at Week 24.
- Adalimumab Induction Regimen (Type: EXPERIMENTAL): Double-blind period (Weeks 0-8): adalimumab 160 mg at Weeks 0 and 80 mg at Week 2, followed by adalimumab 40 mg at Week 4 and Week 6.~Open label period: adalimumab 40 mg eow from Week 8 through last dose at Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).